ImmunoGen Stock News

The Regional Bank Fiasco is a classic “Baby with the Bathwater” scenario. Rising rates are great for Insurance companies and “hidden banks”.

ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed

Commercial-state biotechnology company ImmunoGen Inc. NASDAQ: IMGN shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for progre

ImmunoGen Inc stock more than doubled after the company shared positive topline data from the Phase 3 confirmatory MIRASOL trial evaluating the safety and effectiveness of its experimental ovarian can

The company said it anticipates asking for full approval of Elahere from the FDA. The drug was granted accelerated approval in November to treat advanced ovarian cancer.

The mean of analysts' price targets for ImmunoGen (IMGN) points to a 101.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy

ImmunoGen (NASDAQ: IMGN ) stock is rising higher on Wednesday after the company released results from a Phase 3 trial for treating ovarian cancer. According to a press release, the company reported po

Shares of Immunogen Inc. IMGN blasted 121.2% higher on heavy volume toward a five-year high in premarket trading Wednesday, after the biopharmaceutical company revealed positive data from a late-stage

Markets were waiting to see what the Federal Reserve will do with interest rates later today. Eli Lilly announced favorable trial results for its Alzheimer's treatment.

ImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug Elahere. The company raises financial guidance for 2023.

ImmunoGen Inc shares rocketed higher Friday after the company's first quarter sales impressed investors.  The Massachusetts-based company posted revenue of $49.9 million, including $29.5 million of n

ImmunoGen's ovarian cancer therapy, Elahere, has had a strong launch. The company increased its revenue guidance for 2023.

ImmunoGen (IMGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.10 per share a year ago.

5 penny stocks to watch. The post 5 Hot Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will ho